Document is current
Any future updates will be listed below
-
Authors
Deodhar, Atul https://orcid.org/0000-0002-2130-1246
Nowak, Miroslawa
Ye, June Y.
Lehman, Tom
Banerjee, Subhashis
Mease, Philip J.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03881059 at ClinicalTrials.govDocuments that mention this clinical trial
POS1039 DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS
https://doi.org/10.1136/annrheumdis-2022-eular.1849
POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2022-eular.2468
OP0227 EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2653
AB0437 SEX- AND TREATMENT-ASSOCIATED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.1848
POS0198 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2603
AB0560 EFFECT OF DEUCRAVACITINIB ON THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PsAID) QUESTIONNAIRES 12 AND 9: ANALYSIS OF A PHASE 2 STUDY OF ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.2709
Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis
https://doi.org/10.1007/s40744-025-00776-4
AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.1377
AB0891 Deucravacitinib Efficacy in Psoriatic Arthritis by Baseline DMARD Use: Exploratory Analysis From a Phase 2 Study
https://doi.org/10.1136/annrheumdis-2022-eular.1391
AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.245
AB0459 BASELINE (BL) DEMOGRAPHICS AND DISEASE CHARACTERISTICS BY MENOPAUSAL STATUS AND SEX IN PATIENTS FROM A PHASE 2 TRIAL OF DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
https://doi.org/10.1136/annrheumdis-2024-eular.1873
AB0458 DEUCRAVACITINIB, A SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN ACTIVE PSA: ASSESSMENT OF DIRECT AND INDIRECT IMPACT ON PAIN AND FATIGUE OUTCOMES BY MEDIATION ANALYSIS IN A PHASE 2 CLINICAL TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.1841
AB0409 IMPROVEMENT IN PAIN-ASSOCIATED BIOMARKERS WITH DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA) IN A DOUBLE-BLIND PHASE 2 STUDY (IM011-084)
https://doi.org/10.1136/annrheumdis-2024-eular.1877
AB0886 The Impact of Deucravacitinib on Health-Related Quality of Life Measured by the Short Form Health Survey 36-Item Questionnaire: Analysis of a Phase 2 Trial in Patients With Active Psoriatic Arthritis
https://doi.org/10.1136/annrheumdis-2022-eular.1283
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2021-221664
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 23 May 2025
First Online: 5 July 2025
Declarations
:
: Atul Deodhar: Consulting and/or advisory boards: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, UCB; Research grants: AbbVie, Bristol Myers Squibb, Celgene, MoonLake Immunotherapeutics, Lilly, Novartis, Pfizer, UCB. Miroslawa Nowak and Tom Lehman: Employees and shareholders: Bristol Myers Squibb. June Y. Ye and Subhashis Banerjee: Employees and shareholders: Bristol Myers Squibb at the time of the study; Currently affiliated with Artiva Biotherapeutics. Philip J. Meese: Research grants: AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, UCB; Consulting and/or speaker fees: AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galápagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, UCB, Ventyx Biosciences, XinThera.
: This study was conducted in accordance with the Declaration of Helsinki of 1964, and its later amendments, the International Conference on Harmonisation Guidelines for Good Clinical practice and local regulations. An institutional review board or independent ethics committee at each site approved all study documents, including the protocol, consent form and any other written information provided to patients. All participants provided informed consent to participate in the study before taking part [].
